Klinikum Osnabrück GmbH
- Address
- lock Available on a paid plan
Nervous System Diseases
At Klinikum Osnabrück GmbH, research in Nervous System Diseases focuses on difficult-to-control seizure disorders, including refractory focal onset epilepsy, focal epilepsy, primary generalized tonic-clonic seizures, and status epilepticus in older adults. These studies are designed to assess new treatment options and improve seizure control, safety, and overall effectiveness of care.
- Testing new therapies for refractory status epilepticus and established status epilepticus
- Evaluating seizure reduction in focal onset seizures and primary generalized tonic-clonic seizures
- Assessing safety and tolerability of emerging anti-seizure treatments
These trials aim to expand options for patients whose epilepsy remains uncontrolled with standard treatment, while also generating evidence for better symptom management in clinical practice.
Neoplasms
The site also conducts clinical research in Neoplasms, especially multiple myeloma and chronic lymphocytic leukemia. The main goal is to improve cancer treatment outcomes by comparing combination strategies, strengthening response rates, and exploring approaches that may delay disease progression.
- Studying treatment effectiveness in multiple myeloma and high-risk multiple myeloma
- Evaluating maintenance and induction strategies to improve minimal residual disease outcomes
- Investigating new options for previously untreated chronic lymphocytic leukemia
These oncology trials reflect a strong interest in refining therapy for blood cancers and identifying regimens that may offer deeper and more durable responses.
Hemic and Lymphatic Diseases
Within Hemic and Lymphatic Diseases, the research portfolio centers on multiple myeloma and chronic lymphocytic leukemia. The studies are aimed at testing newer treatment combinations, improving response quality, and examining whether patients can achieve better long-term disease control.
- Comparing treatment combinations in newly diagnosed multiple myeloma
- Assessing MRD negativity as a marker of deeper treatment response
- Exploring new therapeutic strategies for treatment-naive chronic lymphocytic leukemia
At Medizinische Klinik III, these hematology trials support efforts to optimize care for patients with complex blood cancers and to improve outcomes beyond standard treatment approaches.
Supportive Care and Treatment-Related Toxicity
Another important area of research addresses treatment-related complications in cancer care, particularly chemotherapy-induced polyneuropathy. The studies aim to reduce nerve damage and improve quality of life for people receiving chemotherapy.
- Preventing chemotherapy-induced polyneuropathy during cancer treatment
- Reducing the severity of nerve-related symptoms linked to chemotherapy
- Improving patient comfort and daily functioning during oncology care
This work adds a supportive-care dimension to the site’s oncology research, with a practical focus on making cancer treatment more tolerable for patients.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 3 therapeutic areas and 15 of 20 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 6 by active trials.
lock +5 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
lock +2 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 2 161 other sites in Germany
Therapeutic Area Benchmark — Germany
Select a therapeutic area to compare against other sites in Germany.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Germany
Market Share
Country: Germany
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Klinikum Osnabrück GmbH
lock Showing 1 of 11 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| Comparative Effectiveness of Levetiracetam and Valproate Semisodium in Benzodiazepine-Resistant Status Epilepticus in Patients Aged 65 and Older | Universitaet Leipzig | Phase III | Recruiting | Feb 2024 | — |
IMP list
lock Showing 1 of 20 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Isatuximab | 4 | Unknown | 2017-08-15 | 2024-04-03 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.